2-(1-Ethylpropyl)pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(1-Ethylpropyl)pyrazine
• 英文别名: 2-pentan-3-ylpyrazine
• 化学式: C₉H₁₄N₂
• 分子量: 150.22
• InChiKey: RMRVGSBHOQLIOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Boger Dale L.

  公开号：US20090270421A1

  公开（公告）日：2009-10-29

  Potent inhibitors of fatty acid amide hydrolase (FAAH) are constructed having K i 's below 200 pM and activities 10 2 -10 3 times more potent than the corresponding trifluoromethyl ketones. The potent inhibitors combine several features, viz.: 1.) an α-keto heterocylic head group; 2.) a hydrocarbon linkage unit employing an optimal C12-C8 chain length; and 3.) a phenyl or other π-unsaturation corresponding to the arachidonyl Δ 8,9 /Δ 11,12 and/or oleyl Δ 9,10 positions. A preferred α-keto heterocylic head group is α-keto N4 oxazolopyridine, with incorporation of a second weakly basic nitrogen. Fatty acid amide hydrolase is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors).

  具有Ki值低于200 pM的脂肪酸酰胺水解酶（FAAH）的强效抑制剂被构建出来，其活性比相应的三氟甲基酮高102-103倍。这些强效抑制剂结合了几个特征，即：1）α-酮杂环头基团；2）使用最佳C12-C8链长的烃链连接单元；和3）与花生四烯酸Δ8,9/Δ11,12和/或油酸Δ9,10位置相对应的苯基或其他π-不饱和度。首选的α-酮杂环头基团是α-酮N4噁唑吡啶，并结合第二个弱碱性氮。脂肪酸酰胺水解酶是一种酶，负责降解油酰胺（一种内源性诱导睡眠的脂质）和阿那达胺（一种内源性的大麻素受体配体）。
• PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY
  申请人：MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN

  公开号：US20160008339A1

  公开（公告）日：2016-01-14

  The present invention relates to compound characterized by a general formula 1, wherein R 1 is a aryl or a heteroaryl, and —R 2 and R 3 independently of each other are hydrogen or a C 1 -C 5 alkyl, but at least one of R 2 and R 3 is not hydrogen, or together are a C 3 or C 4 alkyl forming a 5- or 6 membered ring, for use in a method for treating of heart failure, hypertension, cardiac hypertrophy or cancer.

  本发明涉及一种化合物，其具有一般式1的特征，其中R1是芳基或杂环基，而-R2和R3各自独立地是氢或C1-C5烷基，但至少有一个R2和R3不是氢，或者一起是C3或C4烷基形成5或6元环，用于治疗心力衰竭、高血压、心脏肥大或癌症的方法。
• Inhibitors of fatty acid amide hydrolase
  申请人：The Scripps Research Institute

  公开号：EP2093220A2

  公开（公告）日：2009-08-26

  Improved competitive inhibitors of fatty acid amide hydrolase (FAAH) employ an alpha-keto heterocyclic pharmacophore and a binding subunit having a pi-unsaturation. The alpha-keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferably by a hydrocarbon chain. The improvement lies in the use of a heterocyclic pharmacophore selected from oxazoles, oxadiazoles, thiazoles, and thiadiazoles that have alkyl or aryl substituents at their 4 and/or 5 positions. The improved competitive inhibitors of FAAH display enhanced activity over conventional competitive inhibitors of FAAH.

  改进的脂肪酸酰胺水解酶（FAAH）竞争性抑制剂采用了α-酮杂环药源和具有对不饱和度的结合亚基。α-酮杂环药基和结合亚基彼此连接，最好是通过烃链连接。改进之处在于使用了选自噁唑、噁二唑、噻唑和噻二唑的杂环嗜药体，这些杂环嗜药体的 4 和/或 5 位具有烷基或芳基取代基。与传统的 FAAH 竞争性抑制剂相比，改进的 FAAH 竞争性抑制剂显示出更强的活性。
• ACTIVE SUBSTANCE AGAINST PROTOZOA
  申请人：Christian-Albrechts-Universität zu Kiel

  公开号：EP3936128A1

  公开（公告）日：2022-01-12

  The present invention relates to active substances against protozoa, especially against Plasmodium spp., e.g. against Plasmodium falciparum, Plasmodium vivax, P. malariae, P. ovale , P. knowlesi, against Toxoplasma spp., e.g. Toxoplasma gondii, against Entamoeba histolytica, against Naegleria fowleri, and relates to a method of treatment and/or prophylaxis of an infection by a protozoon. The active substances are suitable for use in the treatment of and/or for use in prophylaxis of an infection by a protozoon. The active substances have the advantage of having activity against wild-type protozoa, especially against Plasmodium spp. and against Toxoplasma spp. and against Entamoeba histolytica and against Naegleria fowleri, and of having activity also against a mutant of P. falciparum that has been identified as resistant against other anti-malarial active substances.

  本发明涉及抗原生动物的活性物质，尤其是抗疟原虫的活性物质，例如抗恶性疟原虫、间日疟原虫、疟疾疟原虫、卵形疟原虫、克雷西疟原虫，抗弓形虫的活性物质、这些活性物质还涉及治疗和/或预防原生动物感染的方法。这些活性物质适用于治疗和/或预防原生动物感染。这些活性物质的优点是对野生型原生动物具有活性，特别是对疟原虫属、弓形虫属、组织溶解恩塔米 巴虫和瑙格勒氏菌，以及对已确定对其他抗疟疾活性物质具有抗药性的恶性疟原虫突变体具有活性。
• Spirocyclic compounds as tryptophan hydroxylase inhibitors
  申请人：Roivant Sciences GmbH

  公开号：US10350208B2

  公开（公告）日：2019-07-16

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及的螺环化合物是色氨酸羟化酶（TPH），特别是同工酶 1（TPH1）的抑制剂，可用于治疗与外周血清素相关的疾病或失调，例如包括胃肠道、心血管、肺、炎症、代谢和低骨量疾病，以及血清素综合征和癌症。

表征谱图